motility and morphology through the second messenger PIP3. Studies have reported that the P110α (PIK3CA), the catalytic subunit of PI3-kinase is somatically mutated in human cancers. Here, we found ... PIK3CA mutations…
RACEMASE, and 34 beta E12 stainings. Molecular detection of KRAS, BRAF, NRAS, PIK3CA, ALK, ERBB2, DDR2, MAP2K1, RET, and EGFR gene mutational analysis has also been performed. Molecular findings
researchers investigate about reason of BCa. Especially, they detected some important genes (BRCA1/2, PIK3CA, MED12, CDH1, TP53, PTEN or SALL4) for BCa diagnosis or treatment. For this reason
inhibitors may be improved by identifying suitable biomarker(s). One such promising biomarker is PIK3CA, which encodes phosphoinositide 3-kinase catalytic subunit α isoform; mutations in this gene may predict
KRAS wild-type (WT) counterpart. We retrospectively investigated the prognostic role of KRAS, BRAF, PIK3CA (exon 20) mutations and loss of PTEN in surgically resected lung metastases. Lung specimens from ... KRAS WT…
this alteration are KRA5 (15% to 30%), β-catenin/CTNNB1 (14% to 44%), PIK3CA (26% to 36%), PAX 2 (77%) and microsatellite repair factors (20% to 45%). PIK3CA and PIK3R1 ... PIK3CA and PIK3R1 mutations are usually…
PTEN-mTOR signaling pathway is one of the most frequently deregulated pathways in cancer. PIK3CA mutations are found 11%-33% of head and neck cancer (HNC). The hotspot mutation sites ... PIK3CA are E542K, E545K and…
more likely to have clinical events or disease progression. An example is PIK3CA mutation status in women with HER2-positive metastatic breast cancer undergoing first line therapy. It has been ... reported that women…
related to somatic mutations in the Phosphatidylinositol-4-5-biphosphate 3 Kinase Catalytic subunit (PIK3CA) gene, therefore, classified as a PIK3CA-related overgrowth spectrum. These mutations affect the embryological…
mutant patients, genes with a high mutation rate mainly included APC, TP53, PIK3CA, Smad4, and Fbxw7, and in RAS wild-type patients, genes with a high mutation rate mainly included ... while they were only 3% in the RAS…
used to evaluate circulating-tumor DNA and analyzed for mutations using next generation sequencing. PIK3CA mutations were identified in both cases allowing the use of FDA approved PIK3CA-directed treatment
mutations with low variant allele fraction (≤ 30%). Of them, there are 8 TP53, 3 PIK3CA, 2 KRAS and 2 GNAS mutations, and one each of SLC25A19, OTC, PACS1, FLG, NCF4 ... analysis revealed that 4 pathogenic mosaic…
CDKL5, FOXG1, NTNG1, pathogenic mutations were not detected. No mutations were found in the PIK3CA and AGGF1 genes associated with Klippel-Trénaunay syndrome. In the genes ACVRL1, AKT1, CCBE1, CCM2 ... FLT4, FOXC2…
mutations with low variant allele fraction (≤ 30%). Of them, there are 8 TP53, 3 PIK3CA, 2 KRAS and 2 GNAS mutations, and one each of SLC25A19, OTC, PACS1, FLG, NCF4 ... analysis revealed that 4 pathogenic mosaic…
mutation which may predispose to breast carcinogenesis. We found a post-zygotic mosaic mutation PIK3CA p.F1002C with 2% variant allele fraction (VAF) in normal tissue, whose respective VAF during
identifying the frequencies of genetic changes in six frequently mutated genes: KRAS, NRAS, BRAF, PIK3CA, PTEN and TP53 in Egyptian CRC patients. The secondary objective was to validate the next ... males 42.9% with M/F…
Oncogenic PIK3CA mutations are common in endometrial cancers and the PI3K/AKT/mTOR pathway is targetable by drugs. We sought to investigate whether the combination of an mTOR inhibitor, everolimus ... combination in…
variants. In this case missense mutations detected were in KDR c.1416A>T; in PIK3CA c.1173A>G; and in TP53 c.215C>G; respectively. Coverage data analysis showed that ... JAK3, c.352C>T in IDH1, c.2758C>G in ERBB4…
identifying the frequencies of genetic changes in six frequently mutated genes: KRAS, NRAS, BRAF, PIK3CA, PTEN and TP53 in Egyptian CRC patients. The secondary objective was to validate the next ... males 42.9% with M/F…
pancreatic tissues were examined in 45 patients with histologically verified PDAC. KRAS, BRAF and PIK3CA gene mutation analysis was performed using the KRAS/BRAF/PIK3CA array. The transcript profile
Dasatinib-sensitive DLBCL lines were made resistant by transduction of a constitutively active PIK3CA mutant (PIK3CA-H1047R) and the suppression of AKT activation by mTORC2 inhibitors can revert Dasatinib resistance
present in more than 30% of LGSCs and 40% of mucinous ovarian carcinomas. PIK3CA activating mutations are present in more than 35% of OCCCs and more than 20% of ovarian ... months. A preclinical study by our group…